Table 3.
DAS and individual measures of the DAS
| Men | Women | |||||
|---|---|---|---|---|---|---|
| CC (N = 22) | CT (N = 21) | TT (N = 9) | CC (N = 31) | CT (N = 42) | TT (N = 11) | |
| DAS44 at baseline, mean (SD) | 2.95 (0.97) | 3.62 (1.13) | 3.19 (0.73) | 2.96 (0.83) | 3.42 (0.82) | 3.39 (0.92) |
| SJC-baseline | 7.5 (2–23) | 12 (2–25) | 8 (2–21) | 5 (1–19) | 7.5 (1–23) | 5 (2–14) |
| RAI-baseline | 5 (0–19) | 6 (0–20) | 5 (2–12) | 7 (0–15) | 7 (0–31) | 7 (2–50) |
| ESR-baseline | 21(1–74) | 26.5 (9–76) | 16 (3–81) | 18 (1–51) | 25.5 (5–69) | 24 (13–78) |
| GH-baseline | 45.5 (9–100) | 50.0 (5–95) | 47 (11–80) | 52 (9–91) | 59.5 (5–99) | 50 (1–83) |
| DAS44-2 weeks, mean (SD) | 1.53 (0.74) | 2.47 (1.33) | 2.40 (1.02) | 2.24 (0.90) | 2.50 (0.99) | 2.76 (1.29) |
| SJC-2 weeks | 2.5 (0–7) | 5 (2–26) | 5 (2–11) | 2 (0–12) | 3.5 (0–14) | 5 (0–12) |
| RAI-2 weeks | 1 (0–8) | 4 (0–32) | 3 (0–16) | 4 (0–18) | 5 (0–25) | 7 (0–19) |
| ESR-2 weeks | 8 (1–55) | 13 (1–71) | 11 (1–47) | 13 (1–42) | 15 (2–69) | 21 (6–28) |
| GH-2 weeks | 15 (0–69) | 23 (0–100) | 40 (2–67) | 30 (0–76) | 32 (0–100) | 30 (2–80) |
Absolute levels of DAS and individual measures of the DAS at baseline and after GC bridging therapy according to GLCCI1 genotype and gender. Individual measures of the DAS are given as median (range)
SJC swollen joint count, RAI Ritchie articular index, ESR erythrocyte sedimentation rate, GH general health at a 100 mm scale